<DOC>
	<DOCNO>NCT00236184</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy rabeprazole sodium 10 mg treat frequent heartburn .</brief_summary>
	<brief_title>E3810-A001-313 : Efficacy Safety 10 mg Rabeprazole Treating Heartburn Frequent Sufferers</brief_title>
	<detailed_description>This multicenter , double-blind , randomize , placebo-controlled study investigate safety efficacy rabeprazole 10 mg treat frequent heartburn . The study last five week consist follow three phase : one two week screen period include one-week , single-blind , placebo run-in phase , two week double-blind , randomize treatment phase , one week single-blind , placebo follow-up phase .</detailed_description>
	<mesh_term>Heartburn</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>1 . Male female patient &gt; 18 year age . 2 . If female , childbearing potential reason surgery menopause , childbearing potential , use approve method contraception since last menstrual period . Females childbearing potential must negative serum pregnancy test start study . 3 . Patients must report history heartburn least two day per week past month . 1 . History erosive esophagitis verify endoscopy . 2 . History gastroesophageal reflux disease ( GERD ) diagnose physician . 3 . Patients history Barrett 's esophagus esophageal stricture . 4 . Evidence medical condition may interfere conduct study , interpretation study result , health patient study . 5 . Patients require continuous use proton pump inhibitor , histamine receptor ( H2 ) blocker , prokinetics . Prior intermittent use agent permit discontinue least three day prior runin phase . The H2 blocker , cimetidine ( TagametÂ® ) , must discontinue least seven day study drug administer .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>